IntelGenx Technologies (IGXT) 10-Q 9 Nov 23 2023 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2023	Nov. 09, 2023
Document and Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2023
Entity Registrant Name	INTELGENX TECHNOLOGIES CORP.
Entity Central Index Key	0001098880
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Common Stock, Shares Outstanding		174,658,097
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Entity Shell Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Emerging Growth Company	false
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	6420 Abrams
Entity Address, City or Town	Ville Saint Laurent
Entity Address, State or Province	QC
Entity Address, Postal Zip Code	H4S 1Y2
Entity Address, Country	CA
City Area Code	514
Local Phone Number	331-7440
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	000-31187
Entity Tax Identification Number	87-0638336

Consolidated Balance Sheet (Una

Consolidated Balance Sheet (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current
Cash	$ 1,904	$ 1,210
Short-term investments	173	1,317
Accounts receivable	606	709
Prepaid expenses	282	137
Investment tax credits receivable	91	159
Security deposits	74	194
Inventory	81	62
Total current assets	3,211	3,788
Leasehold improvements and equipment, net	3,976	4,425
Security deposits	245	245
Operating lease right-of-use-asset	681	732
Total assets	8,113	9,190
Current
Accounts payable and accrued liabilities	3,193	2,102
Current portion of operating lease liability	243	236
Current portion of finance lease liability	89	36
Deferred revenue	291	0
Total current liabilities	3,816	2,374
Long-term debt	8,500	5,500
Convertible notes	6,371	4,272
Operating lease liability	275	425
Finance lease liability	57	42
Total liabilities	19,019	12,613
Contingencies
Shareholders' deficit
Capital stock, common shares, $0.00001 par value; 450,000,000 shares authorized; 174,658,096 shares issued and outstanding (2022: 174,646,196 common shares)	1	1
Additional paid-in capital	68,337	67,340
Accumulated deficit	(77,077)	(68,530)
Accumulated other comprehensive loss	(2,167)	(2,234)
Total shareholders' deficit	(10,906)	(3,423)
Total liabilities and shareholders' equity	$ 8,113	$ 9,190

Consolidated Balance Sheet (U_2

Consolidated Balance Sheet (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Common stock, par value per share	$ 0.00001	$ 0.00001
Common stock, shares authorized	450,000,000	450,000,000
Common stock, shares, issued	174,658,096	174,646,196
Common stock, shares, outstanding	174,658,096	174,646,196

Consolidated Statement of Share

Consolidated Statement of Shareholders' Equity (Unaudited) - 9 months ended Sep. 30, 2023 - USD ($) $ in Thousands	Capital stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]	Total
Beginning Balance at Dec. 31, 2022	$ 1	$ 67,340	$ (68,530)	$ (2,234)	$ (3,423)
Beginning Balance (Shares) at Dec. 31, 2022	174,646,196
Other comprehensive income				67	67
Issuance of warrants to atai Life Sciences (net of transaction costs of $82)		693			693
Stock options exercised		2			2
Stock options exercised (in shares)	11,900
Agents' warrants issued		19			19
Stock-based compensation		283			283
Net loss for the period			(8,547)		(8,547)
Ending Balance at Sep. 30, 2023	$ 1	$ 68,337	$ (77,077)	$ (2,167)	$ (10,906)
Ending Balance (Shares) at Sep. 30, 2023	174,658,096

Consolidated Statement of Sha_2

Consolidated Statement of Shareholders' Equity (Unaudited) (Parenthetical) $ in Thousands	9 Months Ended
	Sep. 30, 2023 USD ($)
Statement of Stockholders' Equity [Abstract]
Warrants Transaction Cost	$ 82

Consolidated Statement of Compr

Consolidated Statement of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Statement of Operations [Abstract]
Revenues	$ 318	$ 142	$ 613	$ 777
Total revenues	318	142	613	777
Expenses
Research and development expense	867	704	2,503	2,289
Manufacturing expenses	283	429	1,192	1,381
Selling, general and administrative expense	1,338	1,204	3,851	3,405
Depreciation of tangible assets	200	196	587	587
Total expenses	2,688	2,533	8,133	7,662
Operating loss	(2,370)	(2,391)	(7,520)	(6,885)
Finance and interest income	1	1	28	2
Financing and interest expense	(390)	(286)	(1,055)	(1,063)
Net financing and interest expense	(389)	(285)	(1,027)	(1,061)
Net Loss	(2,759)	(2,676)	(8,547)	(7,946)
Other comprehensive income (loss)
Foreign currency translation	213	27	36	55
Change in fair value	(1)	(326)	31	(1,348)
Total other comprehensive loss	212	(299)	67	(1,293)
Comprehensive loss	$ (2,547)	$ (2,975)	$ (8,480)	$ (9,239)
Basic weighted average number of shares outstanding (in shares)	174,658,096	174,621,253	174,653,388	161,446,007
Diluted weighted average number of shares outstanding (in shares)	174,658,096	174,621,253	174,653,388	161,446,007
Basic loss per common share (in dollars per share)	$ (0.01)	$ (0.02)	$ (0.05)	$ (0.06)
Diluted loss per common share (in dollars per share)	$ (0.01)	$ (0.02)	$ (0.05)	$ (0.06)

Consolidated Statement of Cash

Consolidated Statement of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating activities
Net loss	$ (2,759)	$ (2,676)	$ (8,547)	$ (7,946)
Depreciation of tangible assets	200	196	587	587
Stock-based compensation	103	31	283	94
Accretion expense	65	43	169	226
DSU expense	(103)	(58)	57	(143)
Interest paid by issuance of common shares	0	171	0	171
Lease non-cash expense	0	1	1	2
Total Adjustment	(2,494)	(2,292)	(7,450)	(7,009)
Changes in non-cash items related to operations:
Accounts receivable	92	(1)	103	91
Prepaid expenses	(57)	8	(145)	(7)
Investment tax credits receivable	116	132	68	343
Inventory	2	8	(19)	(18)
Security deposits	120	0	120	(9)
Accounts payable and accrued liabilities	504	66	1,033	(165)
Deferred revenues	291	0	291	(189)
Net change in non-cash items related to operations	1,068	213	1,451	46
Net cash used in operating activities	(1,426)	(2,079)	(5,999)	(6,963)
Financing activities
Issuance of loan	0	0	3,000	3,000
Finance lease payments	(16)	(7)	(36)	(25)
Proceeds from atai private placement	2,220	0	2,220	0
Transactions costs of atai private placement	(234)	0	(234)	0
Proceeds from exercise of stock options	0	0	2	0
Net proceeds from convertible notes	0	0	697	0
Transaction costs of convertible notes	0	0	(40)	0
Net cash provided by (used in) financing activities	1,970	(7)	5,609	2,975
Investing activities
Additions to leasehold improvements and equipment	(20)	(141)	(117)	(247)
Redemption of short-term investments	600	1,500	1,175	7,219
Acquisition of short-term investments	0	0	0	(5,739)
Net cash provided by investing activities	580	1,359	1,058	1,233
Increase (decrease) in cash	1,124	(727)	668	(2,755)
Effect of foreign exchange on cash	302	250	26	308
Cash
Beginning of period	478	1,975	1,210	3,945
End of period	$ 1,904	$ 1,498	$ 1,904	$ 1,498

Basis of Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation [Text Block]	1. Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete consolidated financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. All such adjustments are of a normal and recurring nature. These financial statements should be read in conjunction with the audited consolidated financial statements at December 31, 2022. Operating results for the nine months ended September 30, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023. IntelGenx Technologies Corp. (and collectively with IntelGenx Corp., our wholly-owned Canadian subsidiary, "IntelGenx" or the "Company") prepares its consolidated financial statements in accordance with accounting principles generally accepted in the United States of America ("USA"). This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. The consolidated financial statements include the accounts of IntelGenx Technologies Corp. and IntelGenx Corp. On consolidation, all inter-entity transactions and balances have been eliminated. The financial statements are expressed in U.S. funds. Management has performed an evaluation of the Company's activities through the date and time these financial statements were issued and concluded that there are no additional significant events requiring recognition or disclosure.

Going Concern

Going Concern	9 Months Ended
	Sep. 30, 2023
Going Concern [Abstract]
Going Concern [Text Block]	2. Going Concern The Company has financed its operations to date primarily through public offerings of its common stock, proceeds from issuance of convertible notes and debentures, bank loans, royalty, up-front and milestone payments, license fees, proceeds from exercise of warrants and options, and research and development revenues. The Company has devoted substantially all of its resources to its drug development efforts, conducting clinical trials to further advance the product pipeline, the expansion of its facilities, protecting its intellectual property and general and administrative functions relating to these operations. The future success of the Company is dependent on its ability to develop its product pipeline and ultimately upon its ability to attain profitable operations. As of September 30, 2023, the Company had cash and short-term investments totaling approximately $2,077. The Company does not have sufficient existing cash and short-term investments to support operations for the next year following the issuance of these financial statements. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Management's plans to alleviate these conditions include pursuing one or more of the following steps to raise additional funding, none of which can be guaranteed or are entirely within the Company's control: Raise funding through the possible sale of the Company's common stock, including public or private equity financings. Raise funding through debt financing. Continue to seek partners to advance product pipeline. Expand oral film manufacturing activities. Initiate contract oral film manufacturing activities. If the Company is unable to raise further capital when needed or on attractive terms, or if it is unable to procure partnership arrangements to advance its programs, the Company would be forced to potentially delay, reduce or eliminate some of its research and development programs and commercial activities. The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The accompanying consolidated financial statements do not include any adjustments or classifications that may result from the possible inability of the Company to continue as a going concern. Should the Company be unable to continue as a going concern, it may be unable to realize the carrying value of its assets and to meet its liabilities as they become due.

Significant Accounting Policies

Significant Accounting Policies	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	3. Significant Accounting Policies Revenue Recognition The Company may enter into licensing and collaboration agreements for product development, licensing, supply and manufacturing for its product pipeline. The terms of the agreements may include non-refundable signing and licensing fees, milestone payments and royalties on any product sales derived from collaborations. These contracts are analyzed to identify all performance obligations forming part of these contracts. The transaction price of the contract is then determined. The transaction price is allocated between all performance obligations on a residual standalone selling price basis. The stand-alone selling price is estimated based on the comparable market prices, expected cost plus margin and the Company's historical experience. Revenue is measured based on a consideration specified in a contract with a customer, and excludes any sales incentives and amounts collected on behalf of third parties. The Company recognizes revenue when it satisfies a performance obligation by transferring control over a product or service to a customer. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue. The following is a description of principal activities - separated by nature - from which the Company generates its revenue. Product revenue The Company recognizes revenue from the sale of its products when the following conditions are met: delivery has occurred; the price is fixed or determinable; the collectability is reasonably assured and persuasive evidence of an arrangement exists. Research and Development Revenue Revenues with corporate collaborators are recognized as the performance obligations are satisfied over time, and the related expenditures are incurred pursuant to the terms of the agreement. Licensing and Collaboration Arrangements Licenses are considered to be right-to-use licenses. As such, the Company recognizes the licenses revenues at a point in time, upon granting the licenses. Milestone payments are considered variable consideration. As such, the Company estimates variable consideration at the most likely amount to which we expect to be entitled. The estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, research and other revenues in the period during which the adjustment is recognized. The process of successfully achieving the criteria for the milestone payments is highly uncertain. Consequently, there is significant risk that the Company may not earn all of the milestone payments for each of its contracts. Royalties are typically calculated as a percentage of net sales realized by the Company's licensees of its products (including their sub-licensees), as specifically defined in each agreement. The licensees' sales generally consist of revenues from product sales of the Company's product pipeline and net sales are determined by deducting the following: estimates for chargebacks, rebates, sales incentives and allowances, returns and losses and other customary deductions in each region where the Company has licensees. Revenues arising from royalties are considered variable consideration. As such, the Company estimates variable consideration at the most likely amount to which we expect to be entitled. The estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. Leasehold Improvements and Equipment Leasehold improvements and equipment are recorded at cost. Provisions for depreciation are based on their estimated useful lives using the methods as follows: On the declining balance method - Laboratory and office equipment 20% Computer equipment 30% On the straight-line method - Leasehold improvements over the lease term Manufacturing equipment 5 - 10 years Upon retirement or disposal, the cost of the asset disposed of and the related accumulated depreciation are removed from the accounts and any gain or loss is reflected in income. Expenditures for repair and maintenance are expensed as incurred. Leases Leases are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: the lease transfers ownership of the asset by the end of the lease term, the lease contains an option to purchase the asset that is reasonably certain to be exercised, the lease term is for a major part of the remaining useful life of the asset or the present value of the lease payments equals or exceeds substantially all of the fair value of the asset. A lease is classified as an operating lease if it does not meet any one of these criteria. Substantially all of the Company's operating leases are comprised of office space and property leases. The finance leases are comprised of laboratory equipment leases. For all leases at the lease commencement date, a right-of-use asset and a lease liability are recognized. The right-of-use asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease. The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any initial costs incurred, consisting mainly of brokerage commissions, less any lease incentives received. All right-of-use assets are reviewed for impairment. The lease liability is initially measured as the present value of the lease payments, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's secured incremental borrowing rate for the same term as the underlying lease. Lease payments included in the measurement of the lease liability comprise the following: the fixed noncancelable lease payments, payments for optional renewal periods where it is reasonably certain the renewal period will be exercised, and payments for early termination options unless it is reasonably certain the lease will not be terminated early. Lease modifications result in remeasurement of the lease liability. Lease expense for operating leases consists of the lease payments plus any initial direct costs, primarily brokerage commissions, and is recognized on a straight-line basis over the lease term. Included in lease expense are any variable lease payments incurred in the period that were not included in the initial lease liability. The Company has elected not to recognize right-of-use assets and lease liabilities for short-tern leases that have a term of 12 months or less. The effect of short-term leases on our right-of-use asset and lease liability was not material.

Inventory

Inventory	9 Months Ended
	Sep. 30, 2023
Inventory Disclosure [Abstract]
Inventory [Text Block]	4. Inventory Inventory as at September 30, 2023 consisted of raw materials in the amount of $81 thousand (2022: $62 thousand).

Leasehold Improvements and Equi

Leasehold Improvements and Equipment	9 Months Ended
	Sep. 30, 2023
Property, Plant and Equipment [Abstract]
Leasehold Improvements and Equipment [Text Block]	5. Leasehold Improvements and Equipment September 30, 2023 December 31, Accumulated Net Carrying Net Carrying Cost Depreciation Amount Amount Manufacturing equipment $ 4,606 $ 1,917 $ 2,689 $ 2,894 Laboratory and office equipment 1,585 1,191 394 419 Computer equipment 155 124 31 34 Leasehold improvements 3,312 2,450 862 1,078 $ 9,658 $ 5,682 $ 3,976 $ 4,425 As at September 30, 2023, no depreciation has been recorded on manufacturing equipment in the amount of $1,718 thousand (2022 - $1,715 thousand) as this equipment is not yet in use.

Bank Indebtedness

Bank Indebtedness	9 Months Ended
	Sep. 30, 2023
Bank Indebtedness [Abstract]
Bank Indebtedness [Text Block]	6. Bank Indebtedness The Company's credit facility is subject to review annually and consists of corporate credits cards of up to CAD$50 thousand ($37 thousand) and $30 thousand, and foreign exchange contracts limited to CAD$425 thousand ($314 thousand).

Loan Payable

Loan Payable	9 Months Ended
	Sep. 30, 2023
Other Liabilities Disclosure [Abstract]
Loan Payable [Text Block]	7. Loan Payable atai Life Sciences ("atai") has granted to the Company a secured loan in the amount of $8,500,000, bearing interest at 8%. The loan is guaranteed by the Company and secured by all present and future movable property, rights and assets of the Company, excluding any intellectual property or technology controlled or owned by the Company. On August 31, 2023, the Company entered into an amending agreement (the "Amending Agreement") in respect of the amended and restated loan agreement dated as of September 14, 2021 (the "Loan Agreement") between the Company, as borrower, and atai, as lender pursuant to which, among other things, the maturity date of the Loan Agreement was extended from January 5, 2024 to January 5, 2025, and the Company granted additional security to atai over any non-licensed intellectual property of the Company (the "Loan Amendment"). On September 30, 2023, the Company and atai also agreed, subject to obtaining TSX and Shareholder approvals, to enter into a second amendment to the Loan Agreement (the "Second Amendment") to provide, among other things, for the ability for atai to convert the principal and accrued interest outstanding under the Loan Agreement into Shares. The interest for the nine-month period ended September 30, 2023 amounts to $501,000 (2022: $311,000) and is recorded in financing and interest expense. The components of the Company's debt are as follows: September 30, 2023 $ December 31, 2022 $ Loan payable to atai 8,500 5,500 Total debt 8,500 5,500 Less: current portion - - Total long-term debt 8,500 5,500

Convertible Notes

Convertible Notes	9 Months Ended
	Sep. 30, 2023
Convertible Notes [Abstract]
Convertible Notes [Text Block]	8. Convertible Notes On August 31, 2023 the Company announced the closing of the first tranche of a non-brokered private placement (the "Offering") of units ("Units") from atai for aggregate gross proceeds of approximately US$3 million, including US$750,000 to be received by the Company pursuant to the Subsequent atai Subscription (as defined below) once the Shareholder Approvals (as defined below) have been obtained. Pursuant to the Offering, (i) United States subscribers can subscribe for Units (the "US Units") at a price of US$1,000 per US Unit, each US Unit being comprised of a US$1,000 principal amount convertible promissory note (the "US Notes") and 5,405 common stock purchase warrants (the "US Warrants"). The US Notes are convertible into shares of common stock of the Company (the "Shares") at the option of the holder at a price of US$0.185 (the "US Conversion Price"), at anytime from the date that is six (6) months following their issuance up to and including August 31, 2026, and bear interest at 12% per annum, payable quarterly, in arrears, with first payment due September 30, 2023 and every 3 months thereafter. The US Warrants entitle the holders thereof to purchase Shares at a price of US$0.26 per Share, for a period of 3 years following their issuance. atai, a significant shareholder and partner of the Company, subscribed for 2,220 US Units for aggregate gross proceeds to the Company of US$2,220,000 (the "Initial atai Proceeds"). In addition, atai committed to subscribe for an additional 750 US Units for additional aggregate proceeds to the Company of US$750,000 (collectively with the Initial atai Proceeds, the "atai Proceeds") on the same terms (the "Subsequent atai Subscription"), subject to the Company obtaining the Shareholder Approvals. On September 30, 2023, the Company and atai agreed, subject to obtaining TSX approval and the Shareholder Approvals, to enter into an amendment (the "Subscription Agreement Amendment") to the subscription agreement entered into by and between the Company and atai in connection with the Offering to provide atai with the right (the "Call Option") to purchase up to an additional 7,401 US Units (the "Call Option Units") at any time prior to August 31, 2026. The Call Option Units, to the extent atai exercises the Call Option in whole or in part, will be issued on the same terms as the US Units, including with respect to the US Conversion Price, maturity date, interest rate and the number of warrants issued in connection therewith. The Subscription Agreement Amendment will provide that the issuance of any Call Option Units will result in a corresponding reduction in atai's remaining purchase right pursuant to the amended and restated securities purchase agreement dated May 14, 2021, which such right to be reduced by the number of Shares issuable upon the conversion of the principal amount outstanding under such issued Call Option Units. IntelGenx intends to use the proceeds of the Offering to fund the Company's wholly-owned Canadian subsidiary, continuing formulation and development efforts related to ongoing collaborations between IGXT and atai as well as working capital and expenses related to the Offering. The proceeds of the Units are attributed to liability and equity components based on the fair value of each component as follows: Gross proceeds Transaction costs Net proceeds Convertible notes $ 1,445 $ 152 $ 1,293 Warrants 775 82 693 $ 2,200 $ 234 $ 1,986 The convertible notes have been recorded as a liability. Total transactions costs in the amount of $152 thousand were recorded against the liability. The accretion expense for the nine-month period ended September 30, 2023 amounts to $9,000 (2022: $Nil). The warrants have been recorded as equity. The components of the convertible notes are as follows: September 30, 2023 Attributed value of net proceeds to convertible notes $ 1,293 Accretion 9 Convertible notes $ 1,302 The interest on the convertible notes for the nine-month period ended September 30, 2023 amounts to $22 thousand (2022: $Nil) and is recorded in financing and interest expense. The proceeds of the Units are attributed to liability and equity components based on the fair value of each component. Management has determined the value attributed to the warrants to be issued upon shareholder approval is $693, resulting in an increase in additional paid-in-capital of $693. On March 21, 2023, the Company announced the closing of an offering by way of private placement to certain investors in the United States of $763 thousand principal amount of 10% convertible notes due March 1, 2027. The Notes will bear interest at a rate of 10% per annum, payable quarterly, and will be convertible into shares of common stock of the Company beginning 6 months after their issuance at a price of $0.20 per Share. Management has determined the value of the agents' warrants to be $19,000. The convertible notes have been recorded as a liability. Total transactions costs in the amount of $126 thousand were recorded against the liability. The accretion expense for the nine-month period ended September 30, 2023 amounts to $13,000 (2022: $Nil). The warrants have been recorded as equity. The components of the convertible notes are as follows: September 30, 2023 Face value of the convertible notes $ 763 Transaction costs (126 ) Accretion 13 Convertible notes $ 650 The interest on the convertible notes for the nine-month period ended September 30, 2023 amounts to $40,000 (2022: $Nil) and is recorded in financing and interest expense. On August 5, 2021, the Company announced the closing of an offering by way of private placement to certain investors in the United States of $2.1 million principal amount of 8% convertible notes due July 31, 2025. The Notes will bear interest at a rate of 8% per annum, payable quarterly, and will be convertible into shares of common stock of the Company beginning 6 months after their issuance at a price of $0.40 per Share. The Company intends to use the proceeds of the Offering for the Montelukast clinical program. In connection with the Offering, the Company paid to an agent a cash commission of approximately $199,525 in the aggregate and issued non-transferable warrants to the agent, entitling the holder to purchase 613,000 common shares at a price of $0.40 per Share until August 4, 2023. On May 8, 2023, the expiry date of these warrants was extended by an additional 12 months to August 4, 2024. The impact of the modification on the financial statements was insignificant. Management has determined the value of the agents' warrants to be $164,000. The convertible notes have been recorded as a liability. Total transactions costs in the amount of $403 thousand were recorded against the liability. The accretion expense for the nine-month period September 30, 2023 amounts to $72,000 (2022: $63,000). The warrants have been recorded as equity. The components of the convertible notes are as follows: September 30, 2023 December 31, Face value of the convertible notes $ 2,101 $ 2,101 Transaction costs (403 ) (403 ) Accretion 191 119 Convertible notes $ 1,889 $ 1,817 The interest on the convertible notes for the nine-month period ended September 30, 2023 amounts to $126,000 (2022: $126,000) and is recorded in financing and interest expense. On May 8, 2018, the Company closed its previously announced offering by way of private placement (the "Offering"). In connection with the Offering, the Company issued 320 units (the "Units") at a subscription price of $10,000 per Unit for gross proceeds of $3,200,000. A related party of the Company participated in the Offering and subscribed for an aggregate of two Units. Each Unit is comprised of (i) 7,940 common shares of the Corporation ("Common Shares"), (ii) a $5,000 convertible 6% note (a "Note"), and (iii) 7,690 warrants to purchase common shares of the Corporation ("Warrants"). Each Note bears interest at a rate of 6% (payable quarterly, in arrears, with the first payment being due on September 1, 2018), matured on June 1, 2021 and is convertible into Common Shares at a conversion price of $0.80 per Common Share. Each Warrant entitled its holder to purchase one Common Share at a price of $0.80 per Common Share until June 1, 2021. In connection with the Offering, the Company paid to the Agents a cash commission of approximately $157,800 in the aggregate and issued non-transferable agents' warrants to the Agents, entitling the Agents to purchase 243,275 common shares at a price of $0.80 per share until June 1, 2021. Management has determined the value of the agents' warrants to be $50,000. The proceeds of the Units are attributed to liability and equity components based on the fair value of each component as follows: Gross proceeds Transaction costs Net proceeds Common stock $ 1,627 $ 167 $ 1,460 Convertible notes 1,086 111 975 Warrants 487 50 437 $ 3,200 $ 328 $ 2,872 On May 19, 2021, the noteholders approved the amendment of the terms of the convertible notes. The maturity date of the convertible notes was extended from June 1, 2021 to October 31, 2024, the interest rate of the notes increased from 6% to 8%, and the conversion price was reduced from $0.80 to $0.44. These amendments were accounted for as an extinguishment and the notes were re-measured at fair value on June 1, 2021. This re-measurement resulted in a gain on extinguishment in the amount of $151,000 recognized in finance and interest income. The components of the convertible notes subsequent to the amendments are as follows: September 30, 2023 December 31, Face value of the convertible notes $ 909 $ 909 Transaction costs (29 ) (29 ) Accretion 78 52 Convertible notes $ 958 $ 932 The convertible notes have been recorded as a liability. Total transactions costs in the amount of $29 thousand were recorded against the liability. The accretion expense for the nine-month period ended September 30, 2023 amounts to $26,000 (2022: $23,000). The interest on the convertible notes for the nine-month period ended September 30, 2023 amounts to $60,000 and is recorded in financing and interest expense (2022: $60,000). On October 15, 2020, the Company announced the closing of an offering by way of private placement to certain investors in the United States of $1.2 million principal amount of 8% convertible notes due October 15, 2024. The Notes will bear interest at a rate of 8% per annum, payable quarterly, and will be convertible into shares of common stock of the Company beginning 6 months after their issuance at a price of $0.18 per Share. The Company intends to use the proceeds of the Offering for working capital purposes. In connection with the Offering, the Company paid to an agent a cash commission of approximately $85,000 in the aggregate and issued non-transferable warrants to the agent, entitling the holder to purchase 482,000 common shares at a price of $0.18 per Share until October 15, 2022. On October 23, 2020, the Company announced the closing of a second tranche of the Notes to certain investors in the United States of $557 thousand principal amount of 8% convertible notes due October 15, 2024. The Notes will bear interest at a rate of 8% per annum, payable quarterly, and will be convertible into shares of common stock of the Company beginning 6 months after their issuance at a price of $0.18 per Share. In connection with the Offering, the Company paid to an agent a cash commission of approximately $39,000 in the aggregate and issued non-transferable warrants to the agent, entitling the holder to purchase 222,800 common shares at a price of $0.18 per Share until October 15, 2022. Management has determined the value of the agents' warrants to be $44,000. The convertible notes have been recorded as a liability. Total transactions costs in the amount of $268 thousand were recorded against the liability. The accretion expense for the nine-month period ended September 30, 2023 amounts to $49,000 (2022: $44,000). The warrants have been recorded as equity. The components of the convertible notes are as follows: September 30, December 31, 2022 Attributed value of net proceeds to convertible notes $ 1,397 $ 1,397 Accretion 175 126 Convertible note 1,572 $ 1,523 The interest on the convertible notes for the nine-month period ended September 30, 2023 amounts to $99,000 (2022: $99,000) and is recorded in financing and interest expense.

Capital Stock

Capital Stock	9 Months Ended
	Sep. 30, 2023
Stockholders' Equity Note [Abstract]
Capital Stock [Text Block]	9. Capital Stock September 30, 2023 December 31, Authorized - 450,000,000 common shares of $0.00001 par value 20,000,000 preferred shares of $0.00001 par value Issued - 174,658,096 (December 31, 2022 -174,646,196) common shares $ 1 $ 1

Additional Paid-In Capital

Additional Paid-In Capital	9 Months Ended
	Sep. 30, 2023
Additional Paid in Capital [Abstract]
Additional Paid-In Capital [Text Block]	10. Additional Paid-In Capital Stock options On September 26, 2023, 60,000 options to purchase common stock were granted to an employee under the 2022 Stock Option Plan. The options have an exercise price of $0.14. The options granted vest over a period of 2 years at a rate of 25% every six months and expire 10 years after the grant date. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $6 thousand. On April 13, 2023, 4,750,000 options to purchase common stock were granted to an Officer under the 2022 Stock Option Plan. The options have an exercise price of $0.17. The options granted vest over a period of 2 years at a rate of 20% every 6 months starting July 1, 2023 and expire 10 years after the grant date. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $589 thousand. On April 4, 2023, 1,000,000 options to purchase common stock were granted to an Officer under the 2022 Stock Option Plan. The options have an exercise price of $0.19. 50% of the options granted vest in 12 months from the grant date. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $62 thousand. The remaining 50% of the options vest upon the achievement of a specific performance target. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $64 thousand. The options expire 10 years after the grant date. On April 4, 2023, 100,000 options to purchase common stock were granted to an Officer under the 2022 Stock Option Plan. The options have an exercise price of $0.19. 50% of the options granted vest over a period of 2 years at a rate of 25% every six months. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $6 thousand. The remaining 50% of the options vest upon the achievement of a specific performance target. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $12 thousand. The options expire 10 years after the grant date. On April 4, 2023, 50,000 options to purchase common stock were granted to an Officer under the 2022 Stock Option Plan. The options have an exercise price of $0.19. The options granted vest over a period of 2 years at a rate of 25% every six months and expire 10 years after the grant date. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $6 thousand. On April 4, 2023, 275,000 options to purchase common stock were granted to employees under the 2022 Stock Option Plan. The options have an exercise price of $0.19. The options granted vest over a period of 4 years at a rate of 25% every twelve months and expire 10 years after the grant date. These options may have accelerated vesting if specific market conditions are met. The market conditions are based on the Company's stock price achieving specified targets over a continuous period of 30 calendar days. If the market conditions are met, the options will immediately vest and become exercisable. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $36 thousand. On January 29, 2023, 310,000 options to purchase common stock were granted to employees under the 2022 Stock Option Plan. The options have an exercise price of $0.24. The options granted vest over a period of 4 years at a rate of 25% every twelve months and expire 10 years after the grant date. These options may have accelerated vesting if specific market conditions are met. The market conditions are based on the Company's stock price achieving specified targets over a continuous period of 30 calendar days. If the market conditions are met, the options will immediately vest and become exercisable. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $55 thousand. On January 20, 2022, 25,000 options to purchase common stock were granted to an employee under the 2016 Stock Option Plan. The options have an exercise price of $0.34. The options granted vest over a period of 2 years at a rate of 25% every six months and expire 10 years after the grant date. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $6 thousand. During the nine-month period ended September 30, 2023, a total of 11,900 stock options were exercised for 11,900 common shares having a par value of $0 in aggregate, for cash consideration of $2 thousand, resulting in an increase in additional paid-in capital of $2 thousand. No stock options were exercised during the nine-month period ended September 30, 2022. Compensation expenses for stock-based compensation of $270 thousand and $94 thousand were recorded during the nine-month periods ended September 30, 2023 and 2022, respectively. An amount of $261 thousand (2022 - $85 thousand) expensed in the nine-month period ended September 30, 2023 relates to stock options granted to employees and an amount of $9 thousand (2022 - $9 thousand) relates to stock options granted to consultants. As at September 30, 2023, the Company has $567 Warrants No warrants were exercised during the nine-month periods ended September 30, 2023 and 2022. Deferred Share Units ("DSUs") On January 29, 2023, 781,250 DSUs have been granted under the DSU Plan, accordingly, an amount of $185 thousand has been recognized in general and administrative expenses. On January 1, 2022, 543,480 DSUs have been granted under the DSU Plan, accordingly, an amount of $197 thousand has been recognized in general and administrative expenses. Performance and Restricted Share Units ("PRSUs") During the nine-month period ended September 30, 2023, the Company granted 400,000 Performance Restricted Share Units to certain employees, which vest if certain market conditions are met. The PRSUs vest based on the achievement of specified market conditions over a performance period of 3 years. The PRSUs expire 3 years after the grant date. The market conditions are based on the Company's stock price achieving specified targets over a continuous period of 30 calendar days. If the market conditions are met, the PRSUs will vest and become payable in shares of the Company's common stock. The PRSUs were accounted for at their fair value, as determined by the Binomial Lattice valuation model, of approximately $23 thousand. As at September 30, 2023, an amount of $4 thousand has been recognized as stock-based compensation in general and administrative expenses. On April 4, 2023, 100,000 rewards have been issued under the RSU Plan having a fair value of $18 thousand. As at September 30, 2023, an amount of $9 thousand has been recognized as stock-based compensation in general and administrative expenses. The RSUs expire 3 years after the grant date. No PRSUs or RSUs were granted during the nine-month period ended September 30, 2022.

Revenues

Revenues	9 Months Ended
	Sep. 30, 2023
Revenue from Contract with Customer [Abstract]
Revenues [Text Block]	11. Revenues The following table presents our revenues disaggregated by revenue source. Sales and usage-based taxes are excluded from revenues: September 30, 2023 September 30, 2022 Research and development agreements $ 462 $ 657 Research and development milestone 125 - Product revenue - 79 Royalties on product sales 26 41 $ 613 $ 777 The following table presents our revenues disaggregated by timing of recognition: September 30, 2023 September 30, 2022 (in U.S. $ thousands) Product and services transferred at point in time $ 151 $ 267 Products and services transferred over time 462 510 $ 613 $ 777 The following table presents our revenues disaggregated by geography, based on the billing addresses of our customers: September 30, 2023 September 30, 2022 Europe $ 469 525 United States 139 147 Canada 5 105 $ 613 $ 777 Remaining performance obligations As at September 30, 2023, the aggregate amount of the transaction price allocated to the remaining performance obligation is $1,891 representing research and development agreements. The Company is also eligible to receive up to $2,428 in research and development milestone payments, approximately 100% of which is expected to be recognized in the next three years; up to $433 in commercial sales milestone payments which are wholly dependent on the marketing efforts of our development partners. In addition, the Company is entitled to receive royalties on potential sales. The Company applies the practical expedient in paragraph 606-10-50-14 and does not disclose information about the remaining performance obligations that have original expected durations of one year or less.

Leases

Leases	9 Months Ended
	Sep. 30, 2023
Leases [Abstract]
Leases [Text Block]	12. Leases Operating leases Substantially all our operating lease right-of-use assets and operating lease liability represents leases for office space and property to conduct our business. The operating lease expense for the nine-month period ended September 30, 2023 included in general and administrative expenses is $195 thousand. The cash outflows from operating leases for the nine-month period ended September 30, 2023 was $194 thousand. The weighted average remaining lease term and the weighted average discount rate for operating leases at September 30, 2023 were 2.4 years and 10%, respectively. The following table reconciles the undiscounted cash flows for the operating leases as at September 30, 2023 to the operating lease liabilities recorded on the balance sheet: Operating Leases 2023 66 2024 267 2025 267 2026 45 Total undiscounted lease payments 645 Less: Interest 127 Present value of lease liabilities $ 518 Current portion of operating lease liability $243 Operating lease liability $275 Finance leases Substantially all our finance lease right-of-use assets and finance lease liability represents leases for laboratory equipment to conduct our business. The cash outflows from finance leases for the nine-month period ended September 30, 2023 was $36 thousand. The weighted average remaining lease term and the weighted average discount rate for finance leases at September 30, 2023 were 1.7 years and 3.94%, respectively. The following table reconciles the undiscounted cash flows for the finance leases as at September 30, 2023 to the finance lease liabilities recorded on the balance sheet: Finance Leases 2023 23 2024 91 2025 36 Total undiscounted lease payments 150 Less: Interest 4 Present value of lease liabilities $ 146 Current portion of finance lease liability $89 Finance lease liability $57

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2023
Related Party Transactions [Abstract]
Related Party Transactions [Text Block]	13. Included in management salaries are $260 thousand (2022 - $48 thousand) for options, PRSUs and RSUs granted to key management personnel under the 2022 Stock Option Plan. The Company considers its Chief Executive Officer, President and Chief Financial Officer, and Vice-Presidents to be key management personnel. Also included in general and administrative expense for the nine-month period ended September 30, 2023 are director fees of $178 thousand (2022 - $167 thousand) and DSU expense of $57 thousand (2022: DSU recovery of $143 thousand). The above related party transactions have been measured at the exchange amount which is the amount of the consideration established and agreed to by the related parties.

Basic and Diluted Loss Per Comm

Basic and Diluted Loss Per Common Share	9 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Basic and Diluted Loss Per Common Share [Text Block]	14. Basic and Diluted Loss Per Common Share Basic and diluted loss per common share is calculated based on the weighted average number of shares outstanding during the period. The warrants, share-based compensation and convertible debenture and notes have been excluded from the calculation of diluted loss per share since they are anti-dilutive.

Contingencies

Contingencies	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Contingencies [Text Block]	15. Contingencies The government authorities have assessed the Company with respect to sales taxes claimed on certain expenses between 2017 and 2020, which the government is denying. The sales tax assessments amount to $315,000 (including interest and penalties of $34,000), which was paid to avoid further interest and penalties. The Company disagrees with the government's position and the sales tax assessments are under appeal. In the event the Company is unsuccessful in its appeal, sales taxes expenses would increase by $281,000 and net earnings would decrease by $281,000.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2023
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Revenue Recognition [Policy Text Block]	Revenue Recognition The Company may enter into licensing and collaboration agreements for product development, licensing, supply and manufacturing for its product pipeline. The terms of the agreements may include non-refundable signing and licensing fees, milestone payments and royalties on any product sales derived from collaborations. These contracts are analyzed to identify all performance obligations forming part of these contracts. The transaction price of the contract is then determined. The transaction price is allocated between all performance obligations on a residual standalone selling price basis. The stand-alone selling price is estimated based on the comparable market prices, expected cost plus margin and the Company's historical experience. Revenue is measured based on a consideration specified in a contract with a customer, and excludes any sales incentives and amounts collected on behalf of third parties. The Company recognizes revenue when it satisfies a performance obligation by transferring control over a product or service to a customer. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue. The following is a description of principal activities - separated by nature - from which the Company generates its revenue. Product revenue The Company recognizes revenue from the sale of its products when the following conditions are met: delivery has occurred; the price is fixed or determinable; the collectability is reasonably assured and persuasive evidence of an arrangement exists. Research and Development Revenue Revenues with corporate collaborators are recognized as the performance obligations are satisfied over time, and the related expenditures are incurred pursuant to the terms of the agreement. Licensing and Collaboration Arrangements Licenses are considered to be right-to-use licenses. As such, the Company recognizes the licenses revenues at a point in time, upon granting the licenses. Milestone payments are considered variable consideration. As such, the Company estimates variable consideration at the most likely amount to which we expect to be entitled. The estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, research and other revenues in the period during which the adjustment is recognized. The process of successfully achieving the criteria for the milestone payments is highly uncertain. Consequently, there is significant risk that the Company may not earn all of the milestone payments for each of its contracts. Royalties are typically calculated as a percentage of net sales realized by the Company's licensees of its products (including their sub-licensees), as specifically defined in each agreement. The licensees' sales generally consist of revenues from product sales of the Company's product pipeline and net sales are determined by deducting the following: estimates for chargebacks, rebates, sales incentives and allowances, returns and losses and other customary deductions in each region where the Company has licensees. Revenues arising from royalties are considered variable consideration. As such, the Company estimates variable consideration at the most likely amount to which we expect to be entitled. The estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved.
Leasehold Improvements and Equipment [Policy Text Block]	Leasehold Improvements and Equipment Leasehold improvements and equipment are recorded at cost. Provisions for depreciation are based on their estimated useful lives using the methods as follows: On the declining balance method - Laboratory and office equipment 20% Computer equipment 30% On the straight-line method - Leasehold improvements over the lease term Manufacturing equipment 5 - 10 years Upon retirement or disposal, the cost of the asset disposed of and the related accumulated depreciation are removed from the accounts and any gain or loss is reflected in income. Expenditures for repair and maintenance are expensed as incurred.
Leases [Policy Text Block]	Leases Leases are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: the lease transfers ownership of the asset by the end of the lease term, the lease contains an option to purchase the asset that is reasonably certain to be exercised, the lease term is for a major part of the remaining useful life of the asset or the present value of the lease payments equals or exceeds substantially all of the fair value of the asset. A lease is classified as an operating lease if it does not meet any one of these criteria. Substantially all of the Company's operating leases are comprised of office space and property leases. The finance leases are comprised of laboratory equipment leases. For all leases at the lease commencement date, a right-of-use asset and a lease liability are recognized. The right-of-use asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease. The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any initial costs incurred, consisting mainly of brokerage commissions, less any lease incentives received. All right-of-use assets are reviewed for impairment. The lease liability is initially measured as the present value of the lease payments, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's secured incremental borrowing rate for the same term as the underlying lease. Lease payments included in the measurement of the lease liability comprise the following: the fixed noncancelable lease payments, payments for optional renewal periods where it is reasonably certain the renewal period will be exercised, and payments for early termination options unless it is reasonably certain the lease will not be terminated early. Lease modifications result in remeasurement of the lease liability. Lease expense for operating leases consists of the lease payments plus any initial direct costs, primarily brokerage commissions, and is recognized on a straight-line basis over the lease term. Included in lease expense are any variable lease payments incurred in the period that were not included in the initial lease liability. The Company has elected not to recognize right-of-use assets and lease liabilities for short-tern leases that have a term of 12 months or less. The effect of short-term leases on our right-of-use asset and lease liability was not material.

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Schedule of estimated useful lives of leasehold improvements and equipment [Table Text Block]	On the declining balance method - Laboratory and office equipment 20% Computer equipment 30% On the straight-line method - Leasehold improvements over the lease term Manufacturing equipment 5 - 10 years

Leasehold Improvements and Eq_2

Leasehold Improvements and Equipment (Tables)	9 Months Ended
	Sep. 30, 2023
Property, Plant and Equipment [Abstract]
Schedule of leasehold improvements and equipment [Table Text Block]	September 30, 2023 December 31, Accumulated Net Carrying Net Carrying Cost Depreciation Amount Amount Manufacturing equipment $ 4,606 $ 1,917 $ 2,689 $ 2,894 Laboratory and office equipment 1,585 1,191 394 419 Computer equipment 155 124 31 34 Leasehold improvements 3,312 2,450 862 1,078 $ 9,658 $ 5,682 $ 3,976 $ 4,425

Loan Payable (Tables)

Loan Payable (Tables)	9 Months Ended
	Sep. 30, 2023
Other Liabilities Disclosure [Abstract]
Schedule of term loan [Table Text Block]	September 30, 2023 $ December 31, 2022 $ Loan payable to atai 8,500 5,500 Total debt 8,500 5,500 Less: current portion - - Total long-term debt 8,500 5,500

Convertible Notes (Tables)

Convertible Notes (Tables)	9 Months Ended
	Sep. 30, 2023
12% convertible notes due August 31, 2026 [Member]
Debt Instrument [Line Items]
Schedule of capital units [Table Text Block]	Gross proceeds Transaction costs Net proceeds Convertible notes $ 1,445 $ 152 $ 1,293 Warrants 775 82 693 $ 2,200 $ 234 $ 1,986
Schedule of components of convertible notes [Table Text Block]	September 30, 2023 Attributed value of net proceeds to convertible notes $ 1,293 Accretion 9 Convertible notes $ 1,302
10% convertible notes due March 1, 2027 [Member]
Debt Instrument [Line Items]
Schedule of components of convertible notes [Table Text Block]	September 30, 2023 Face value of the convertible notes $ 763 Transaction costs (126 ) Accretion 13 Convertible notes $ 650
8% convertible notes due July 31, 2025 [Member]
Debt Instrument [Line Items]
Schedule of components of convertible notes [Table Text Block]	September 30, 2023 December 31, Face value of the convertible notes $ 2,101 $ 2,101 Transaction costs (403 ) (403 ) Accretion 191 119 Convertible notes $ 1,889 $ 1,817
Liability and equity components [Member]
Debt Instrument [Line Items]
Schedule of capital units [Table Text Block]	Gross proceeds Transaction costs Net proceeds Common stock $ 1,627 $ 167 $ 1,460 Convertible notes 1,086 111 975 Warrants 487 50 437 $ 3,200 $ 328 $ 2,872
Amendment to convertible note [Member]
Debt Instrument [Line Items]
Schedule of components of convertible notes [Table Text Block]	September 30, 2023 December 31, Face value of the convertible notes $ 909 $ 909 Transaction costs (29 ) (29 ) Accretion 78 52 Convertible notes $ 958 $ 932
8% convertible notes due Oct 15, 2024 [Member]
Debt Instrument [Line Items]
Schedule of components of convertible notes [Table Text Block]	September 30, December 31, 2022 Attributed value of net proceeds to convertible notes $ 1,397 $ 1,397 Accretion 175 126 Convertible note 1,572 $ 1,523

Capital Stock (Tables)

Capital Stock (Tables)	9 Months Ended
	Sep. 30, 2023
Stockholders' Equity Note [Abstract]
Schedule of stock by class [Table Text Block]	September 30, 2023 December 31, Authorized - 450,000,000 common shares of $0.00001 par value 20,000,000 preferred shares of $0.00001 par value Issued - 174,658,096 (December 31, 2022 -174,646,196) common shares $ 1 $ 1

Revenues (Tables)

Revenues (Tables)	9 Months Ended
	Sep. 30, 2023
Revenue from Contract with Customer [Abstract]
Schedule of disaggregation of revenue [Table Text Block]	September 30, 2023 September 30, 2022 Research and development agreements $ 462 $ 657 Research and development milestone 125 - Product revenue - 79 Royalties on product sales 26 41 $ 613 $ 777
Schedule of revenues disaggregated by timing of recognition [Table Text Block]	September 30, 2023 September 30, 2022 (in U.S. $ thousands) Product and services transferred at point in time $ 151 $ 267 Products and services transferred over time 462 510 $ 613 $ 777
Schedule of revenues disaggregated by geography [Table Text Block]	September 30, 2023 September 30, 2022 Europe $ 469 525 United States 139 147 Canada 5 105 $ 613 $ 777

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2023
Leases [Abstract]
Schedule of undiscounted cash flows for the operating leases [Table Text Block]	Operating Leases 2023 66 2024 267 2025 267 2026 45 Total undiscounted lease payments 645 Less: Interest 127 Present value of lease liabilities $ 518
Schedule of operating lease liabilities [Table Text Block]	Current portion of operating lease liability $243 Operating lease liability $275
Schedule of undiscounted cash flows for the finance leases [Table Text Block]	Finance Leases 2023 23 2024 91 2025 36 Total undiscounted lease payments 150 Less: Interest 4 Present value of lease liabilities $ 146
Schedule of financing lease liabilities [Table Text Block]	Current portion of finance lease liability $89 Finance lease liability $57

Going Concern (Narrative) (Deta

Going Concern (Narrative) (Details) $ in Thousands	Sep. 30, 2023 USD ($)
Going Concern [Abstract]
Cash and short-term investments	$ 2,077

Significant Accounting Polici_4

Significant Accounting Policies - Schedule of estimated useful lives of leasehold improvements and equipment (Details)	9 Months Ended
	Sep. 30, 2023
Laboratory and office equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, depreciation methods	declining balance method
Property plant and equipment, estimated useful life depreciation methods percentage	20%
Computer equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, depreciation methods	declining balance method
Property plant and equipment, estimated useful life depreciation methods percentage	30%
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, depreciation methods	straight-line method
Property plant and equipment, estimated useful live depreciation methods description	over the lease term
Manufacturing equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, depreciation methods	straight-line method
Manufacturing equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	5 years
Manufacturing equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	10 years

Inventory (Narrative) (Details)

Inventory (Narrative) (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Sep. 30, 2022
Inventory Disclosure [Abstract]
Raw materials inventory	$ 81	$ 62

Leasehold Improvements and Eq_3

Leasehold Improvements and Equipment (Narrative) (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022	Sep. 30, 2022
Property, Plant and Equipment [Line Items]
Leasehold improvements and equipment	$ 3,976	$ 4,425
Asset not yet in service [Member]
Property, Plant and Equipment [Line Items]
Leasehold improvements and equipment	$ 1,718		$ 1,715

Leasehold improvements and Eq_4

Leasehold improvements and Equipment - Schedule of leasehold improvements and equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Cost	$ 9,658
Accumulated Depreciation	5,682
Net Carrying Amount	3,976	$ 4,425
Manufacturing equipment [Member]
Property, Plant and Equipment [Line Items]
Cost	4,606
Accumulated Depreciation	1,917
Net Carrying Amount	2,689	2,894
Laboratory and office equipment [Member]
Property, Plant and Equipment [Line Items]
Cost	1,585
Accumulated Depreciation	1,191
Net Carrying Amount	394	419
Computer equipment [Member]
Property, Plant and Equipment [Line Items]
Cost	155
Accumulated Depreciation	124
Net Carrying Amount	31	34
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Cost	3,312
Accumulated Depreciation	2,450
Net Carrying Amount	$ 862	$ 1,078

Bank Indebtedness (Narrative) (

Bank Indebtedness (Narrative) (Details) - Sep. 30, 2023 $ in Thousands, $ in Thousands	CAD ($)	USD ($)
Corporate Credit Cards [Member]
Line of Credit Facility [Line Items]
Long-term Line of Credit	$ 50	$ 37
Corporate Credit Cards 2 [Member]
Line of Credit Facility [Line Items]
Long-term Line of Credit		30
Foreign Exchange Contract [Member]
Line of Credit Facility [Line Items]
Long-term Line of Credit	$ 425	$ 314

Loan Payable (Narrative) (Detai

Loan Payable (Narrative) (Details) - atai Life Sciences [Member] - Secured Loan [Member] - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Debt Instrument [Line Items]
Aggregate principal amount	$ 8,500,000
Interest rate	8%
Loan collateral	The loan is guaranteed by the Company and secured by all present and future movable property, rights and assets of the Company, excluding any intellectual property or technology controlled or owned by the Company.
Loan maturity date	Jan. 05, 2025
Financing and interest expense	$ 501,000	$ 311,000

Loan Payable - Schedule of term

Loan Payable - Schedule of term loan (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Loan payable to atai	$ 8,500	$ 5,500
Total debt	8,500	5,500
Less: current portion	0	0
Total long-term debt	$ 8,500	$ 5,500

Convertible Notes (Narrative) (

Convertible Notes (Narrative) (Details) - USD ($)				1 Months Ended				3 Months Ended		9 Months Ended		12 Months Ended
	Aug. 05, 2021	Oct. 15, 2020	May 08, 2018	Aug. 31, 2023	Mar. 21, 2023	May 19, 2021	Oct. 23, 2020	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Debt Instrument [Line Items]
Convertible notes, conversion price			$ 0.8
Common stock, par value per share								$ 0.00001		$ 0.00001		$ 0.00001
Commission paid to agents			$ 157,800
Warrants issued during period, value			$ 50,000
Accretion expense								$ 65,000	$ 43,000	$ 169,000	$ 226,000
Stock issued during period, shares, conversion of units			320
Subscription price of units			$ 10,000
Stock issued, value, conversion of units			$ 3,200,000
Common stock issued in units			7,940
Share issuance price per share			$ 0.8
Shares issued for services			243,275
Equity issuance, per share amount			$ 0.8
Convertible Debt Securities [Member]
Debt Instrument [Line Items]
Warrants issued during period			7,690
Convertible debt issued in units			$ 5,000
Interest rate on convertible note			6%
Convertible notes [Member]
Debt Instrument [Line Items]
Transaction costs								$ 29,000		29,000
Accretion expense										26,000	23,000
Financing and interest expense										60,000	60,000
Private Placement [Member] | atai Life Sciences [Member]
Debt Instrument [Line Items]
Stock issued during period, shares, conversion of units				2,220
Stock issued during period, additional units subscribed				750
Gross proceeds from additional units subscribed				$ 750,000
Stock issued, value, conversion of units				2,220,000
12% convertible notes due August 31, 2026 [Member]
Debt Instrument [Line Items]
Warrants issued during period, value										693
Transactions costs of convertible notes										152,000
Accretion expense										9,000	0
Financing and interest expense										22	0
Increase in additional paid-in-capital										693
12% convertible notes due August 31, 2026 [Member] | Private Placement [Member] | atai Life Sciences [Member]
Debt Instrument [Line Items]
Gross proceeds from convertible notes				3,000,000
Debt instrument, face amount				$ 1,000
Convertible notes, conversion price				$ 0.185
Common stock, par value per share				$ 0.26
Warrants issued during period				5,405
Subscription price of units				$ 1,000
Stock issued, value, conversion of units				$ 750,000
Interest rate on convertible note				12%
10% convertible notes due March 1, 2027 [Member]
Debt Instrument [Line Items]
Transactions costs of convertible notes										126,000
Accretion expense										13,000	0
Financing and interest expense										40,000	0
10% convertible notes due March 1, 2027 [Member] | Private Placement [Member]
Debt Instrument [Line Items]
Debt instrument, face amount					$ 763,000
Convertible notes percentage					10%
Convertible notes, conversion price					$ 0.2
Commission paid to agents					$ 53,000
Warrants issued during period					304,000
Exercise price of warrants issued					$ 0.2
Warrants issued during period, value					$ 19,000
Transactions costs of convertible notes										126,000
Interest rate on convertible note					10%
8% convertible notes due July 31, 2025 [Member]
Debt Instrument [Line Items]
Transactions costs of convertible notes										403,000		$ 403,000
Accretion expense										72,000	63,000
Financing and interest expense										126,000	126,000
8% convertible notes due July 31, 2025 [Member] | Private Placement [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	$ 2,100,000
Convertible notes percentage	8%
Convertible notes, conversion price	$ 0.4
Commission paid to agents	$ 199,525
Warrants issued during period	613,000
Exercise price of warrants issued	$ 0.4
Warrants issued during period, value	$ 164,000
Transactions costs of convertible notes										403,000
8% convertible notes due Oct 15, 2024 [Member]
Debt Instrument [Line Items]
Financing and interest expense										99,000	99,000
8% convertible notes due Oct 15, 2024 [Member] | Private Placement [Member]
Debt Instrument [Line Items]
Debt instrument, face amount		$ 1,200,000					$ 557,000
Convertible notes percentage		8%					8%
Convertible notes, conversion price		$ 0.18					$ 0.18
Commission paid to agents							$ 39,000
Warrants issued during period		482,000					222,800
Exercise price of warrants issued		$ 0.18					$ 0.18
Warrants issued during period, value							$ 44,000
Transactions costs of convertible notes										268,000
Accretion expense										49,000	$ 44,000
Payments of debt issuance costs		$ 85,000
Amendment to convertible note [Member]
Debt Instrument [Line Items]
Transactions costs of convertible notes										$ 29,000		$ 29,000
Interest rate on convertible note	8%
Gain (Loss) on Extinguishment of Debt						$ 151,000
Amendment to convertible note [Member] | atai Life Sciences [Member] | Call Option [Member]
Debt Instrument [Line Items]
Stock issued during period, shares, conversion of units										7,401
Amendment to convertible note [Member] | Minimum [Member]
Debt Instrument [Line Items]
Convertible notes, conversion price						$ 0.8
Interest rate on convertible note						6%
Amendment to convertible note [Member] | Maximum [Member]
Debt Instrument [Line Items]
Convertible notes, conversion price						$ 0.44
Interest rate on convertible note						8%

Convertible Notes - Schedule of

Convertible Notes - Schedule of capital units (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2023 USD ($)
Debt Instrument [Line Items]
Gross proceeds	$ 3,200
Transaction costs	328
Net proceeds	2,872
Convertible notes [Member]
Debt Instrument [Line Items]
Gross proceeds	1,086
Transaction costs	111
Net proceeds	975
Common stock [Member]
Debt Instrument [Line Items]
Gross proceeds	1,627
Transaction costs	167
Net proceeds	1,460
Warrants [Member]
Debt Instrument [Line Items]
Gross proceeds	487
Transaction costs	50
Net proceeds	437
12% convertible notes due August 31, 2026 [Member]
Debt Instrument [Line Items]
Gross proceeds	2,200
Transaction costs	234
Net proceeds	1,986
12% convertible notes due August 31, 2026 [Member] | Convertible notes [Member]
Debt Instrument [Line Items]
Gross proceeds	1,445
Transaction costs	152
Net proceeds	1,293
12% convertible notes due August 31, 2026 [Member] | Warrants [Member]
Debt Instrument [Line Items]
Gross proceeds	775
Transaction costs	82
Net proceeds	$ 693

Convertible Notes - Schedule _2

Convertible Notes - Schedule of components of the convertible notes (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Convertible notes	$ 6,371	$ 4,272
10% convertible notes due March 1, 2027 [Member]
Debt Instrument [Line Items]
Face value of the convertible notes	763
Transaction costs	(126)
Accretion	13
Convertible notes	650
8% convertible notes due July 31, 2025 [Member]
Debt Instrument [Line Items]
Face value of the convertible notes	2,101	2,101
Transaction costs	(403)	(403)
Accretion	191	119
Convertible notes	1,889	1,817
Amendment to convertible note [Member]
Debt Instrument [Line Items]
Face value of the convertible notes	909	909
Transaction costs	(29)	(29)
Accretion	78	52
Convertible notes	$ 958	$ 932

Convertible Notes - Schedule _3

Convertible Notes - Schedule of components of convertible notes subsequent to the amendments (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Convertible note	$ 6,371	$ 4,272
12% convertible notes due August 31, 2026 [Member]
Debt Instrument [Line Items]
Attributed value of net proceeds to convertible notes	1,293
Accretion	9
Convertible note	1,302
8% convertible notes due Oct 15, 2024 [Member]
Debt Instrument [Line Items]
Attributed value of net proceeds to convertible notes	1,397	1,397
Accretion	175	126
Convertible note	$ 1,572	$ 1,523

Capital Stock - Schedule of sto

Capital Stock - Schedule of stock by class (Details) - USD ($) $ / shares in Units, $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Stockholders' Equity Note [Abstract]
Common stock, shares authorized	450,000,000	450,000,000
Common stock, par value per share	$ 0.00001	$ 0.00001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, par value per share	$ 0.00001	$ 0.00001
Common stock, shares, issued	174,658,096	174,646,196
Common stock, value, issued	$ 1	$ 1

Additional Paid-In Capital (Nar

Additional Paid-In Capital (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands						1 Months Ended	3 Months Ended		9 Months Ended
	Apr. 13, 2023	Apr. 04, 2023	Jan. 29, 2023	Jan. 20, 2022	Jan. 01, 2022	Sep. 26, 2023	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Schedule of Additional Paid In Capital [Line Items]
Stock options exercised									$ 2
Stock based compensation							$ 103	$ 31	283	$ 94
Stock based compensation for options									270	$ 94
Deferred share units [Member]
Schedule of Additional Paid In Capital [Line Items]
Deferred share units grants in period			781,250		543,480
General and administrative expenses			$ 185		$ 197
Performance and restricted share units [Member]
Schedule of Additional Paid In Capital [Line Items]
Number of shares granted										0
Options, expiration period		3 years
Stock based compensation									9
Number of shares issued		100,000
Fair value of issued shares		$ 18
Performance and restricted share units [Member] | Binomial Lattice Valuation Model [Member]
Schedule of Additional Paid In Capital [Line Items]
Stock granted, value, share-based compensation, gross									23
Stock based compensation									$ 4
Common stock [Member]
Schedule of Additional Paid In Capital [Line Items]
Stock options exercised (in shares)									11,900
Additional paid-in capital [Member]
Schedule of Additional Paid In Capital [Line Items]
Stock options exercised									$ 2
Warrant [Member]
Schedule of Additional Paid In Capital [Line Items]
Stock options exercised (in shares)									0	0
Unrecognized stock-based compensation [Member]
Schedule of Additional Paid In Capital [Line Items]
Stock based compensation									$ 567	$ 52
Stock options granted to consultant [Member]
Schedule of Additional Paid In Capital [Line Items]
Stock based compensation									9	9
Employee [Member]
Schedule of Additional Paid In Capital [Line Items]
Stock based compensation									$ 261	$ 85
Employee [Member] | Performance and restricted share units [Member]
Schedule of Additional Paid In Capital [Line Items]
Number of shares granted									400,000
Weighted average remaining contractual term, options vested									3 years
Options, expiration period									3 years
Stock options [Member]
Schedule of Additional Paid In Capital [Line Items]
Stock options exercised (in shares)									11,900	0
Stock options exercised									$ 2
Stock options [Member] | Common stock [Member]
Schedule of Additional Paid In Capital [Line Items]
Stock options exercised (in shares)									11,900
Stock options exercised									$ 0
Stock options [Member] | Additional paid-in capital [Member]
Schedule of Additional Paid In Capital [Line Items]
Stock options exercised									$ 2
Stock options [Member] | Officer [Member] | 2022 Stock Option Plan [Member]
Schedule of Additional Paid In Capital [Line Items]
Number of shares granted	4,750,000	1,000,000
Weighted average exercise price, options granted	$ 0.17	$ 0.19
Weighted average remaining contractual term, options vested	2 years
Vesting rights, percentage	20%
Options, expiration period	10 years	10 years
Stock granted, value, share-based compensation, gross	$ 589
Stock options [Member] | Officer [Member] | 2022 Stock Option Plan [Member] | Share-Based Payment Arrangement, Tranche One [Member]
Schedule of Additional Paid In Capital [Line Items]
Weighted average remaining contractual term, options vested		12 months
Stock granted, value, share-based compensation, gross		$ 62
Stock options [Member] | Officer [Member] | 2022 Stock Option Plan [Member] | Share-Based Payment Arrangement, Tranche Two [Member]
Schedule of Additional Paid In Capital [Line Items]
Vesting rights		the options vest upon the achievement of a specific performance target.
Stock granted, value, share-based compensation, gross		$ 64
Stock options [Member] | Officer One [Member] | 2022 Stock Option Plan [Member]
Schedule of Additional Paid In Capital [Line Items]
Number of shares granted		100,000
Weighted average exercise price, options granted		$ 0.19
Options, expiration period		10 years
Stock options [Member] | Officer One [Member] | 2022 Stock Option Plan [Member] | Share-Based Payment Arrangement, Tranche One [Member]
Schedule of Additional Paid In Capital [Line Items]
Weighted average remaining contractual term, options vested		2 years
Vesting rights, percentage		25%
Stock granted, value, share-based compensation, gross		$ 6
Stock options [Member] | Officer One [Member] | 2022 Stock Option Plan [Member] | Share-Based Payment Arrangement, Tranche Two [Member]
Schedule of Additional Paid In Capital [Line Items]
Vesting rights		the options vest upon the achievement of a specific performance target
Stock granted, value, share-based compensation, gross		$ 12
Stock options [Member] | Officer Two [Member] | 2022 Stock Option Plan [Member]
Schedule of Additional Paid In Capital [Line Items]
Number of shares granted		50,000
Weighted average exercise price, options granted		$ 0.19
Weighted average remaining contractual term, options vested		2 years
Vesting rights, percentage		25%
Options, expiration period		10 years
Stock granted, value, share-based compensation, gross		$ 6
Stock options [Member] | Employee [Member] | 2022 Stock Option Plan [Member]
Schedule of Additional Paid In Capital [Line Items]
Number of shares granted		275,000	310,000			60,000
Weighted average exercise price, options granted		$ 0.19	$ 0.24			$ 0.14
Weighted average remaining contractual term, options vested		4 years	4 years			2 years
Vesting rights, percentage		25%	25%			25%
Options, expiration period		10 years	10 years			10 years
Stock granted, value, share-based compensation, gross		$ 36	$ 55			$ 6
Stock options [Member] | Employee [Member] | 2016 Stock Option Plan [Member]
Schedule of Additional Paid In Capital [Line Items]
Number of shares granted				25,000
Weighted average exercise price, options granted				$ 0.34
Weighted average remaining contractual term, options vested				2 years
Vesting rights, percentage				25%
Options, expiration period				10 years
Stock granted, value, share-based compensation, gross				$ 6

Revenues (Narrative) (Details)

Revenues (Narrative) (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2023 USD ($)
Revenue from Contract with Customer [Abstract]
Transaction price allocated to the remaining performance obligation	$ 1,891
Research and development milestone payments	$ 2,428
Percentages of recognized in next three year	100%
Commercial sales milestone payments	$ 433

Revenues - Schedule of revenue

Revenues - Schedule of revenue disaggregated by revenue source (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Disaggregation of Revenue [Line Items]
Revenue	$ 318	$ 142	$ 613	$ 777
Research and development agreements [Member]
Disaggregation of Revenue [Line Items]
Revenue			462	657
Research and dvelopment milestone [Member]
Disaggregation of Revenue [Line Items]
Revenue			125	0
Product revenue [Member]
Disaggregation of Revenue [Line Items]
Revenue			0	79
Royalties on product sales [Member]
Disaggregation of Revenue [Line Items]
Revenue			$ 26	$ 41

Revenues - Schedule of revenu_2

Revenues - Schedule of revenue disaggregated by timing of recognition (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Disaggregation of Revenue [Line Items]
Revenue	$ 318	$ 142	$ 613	$ 777
Product and services transferred at point in time [Member]
Disaggregation of Revenue [Line Items]
Revenue			151	267
Products and services transferred over time [Member]
Disaggregation of Revenue [Line Items]
Revenue			$ 462	$ 510

Revenues - Schedule of revenu_3

Revenues - Schedule of revenue disaggregated by geography, based on the billing addresses of our customers (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Disaggregation of Revenue [Line Items]
Revenue	$ 318	$ 142	$ 613	$ 777
Europe [Member]
Disaggregation of Revenue [Line Items]
Revenue			469	525
United States [Member]
Disaggregation of Revenue [Line Items]
Revenue			139	147
Canada [Member]
Disaggregation of Revenue [Line Items]
Revenue			$ 5	$ 105

Leases (Narrative) (Details)

Leases (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Leases [Abstract]
Operating lease expense			$ 195
Operating lease payments			$ 194
Weighted average remaining lease term	2 years 4 months 24 days		2 years 4 months 24 days
Weighted average discount rate for operating leases	10%		10%
Cash outflows from finance leases	$ 16	$ 7	$ 36	$ 25
Finance lease weighted average remaining lease term	1 year 8 months 12 days		1 year 8 months 12 days
Weighted average discount rate for finance leases	3.94%		3.94%

Leases - Schedule of leases (De

Leases - Schedule of leases (Details) $ in Thousands	Sep. 30, 2023 USD ($)
Leases [Abstract]
2023	$ 66
2024	267
2025	267
2026	45
Total undiscounted lease payments	645
Less: Interest	127
Present value of lease liabilities	$ 518

Leases - Schedule of operating

Leases - Schedule of operating lease liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Leases [Abstract]
Current portion of operating lease liability	$ 243	$ 236
Operating lease liability	$ 275	$ 425

Leases - Schedule of finance le

Leases - Schedule of finance leases (Details) $ in Thousands	Sep. 30, 2023 USD ($)
Leases [Abstract]
2023	$ 23
2024	91
2025	36
Total undiscounted lease payments	150
Less: Interest	4
Present value of lease liabilities	$ 146

Leases - Schedule of financial

Leases - Schedule of financial lease liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Leases [Abstract]
Current portion of finance lease liability	$ 89	$ 36
Finance lease liability	$ 57	$ 42

Related Party Transactions (Nar

Related Party Transactions (Narrative) (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Options granted to the Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Salaries, Wages and Officers' Compensation	$ 260	$ 48
Director fees [Member]
Related Party Transaction [Line Items]
Salaries, Wages and Officers' Compensation	178	167
Deferred share units [Member]
Related Party Transaction [Line Items]
Salaries, Wages and Officers' Compensation	$ 57	$ 143

Contingencies (Narrative) (Deta

Contingencies (Narrative) (Details)	9 Months Ended
	Sep. 30, 2023 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Sales tax assessments amount	$ 315,000
Sales tax assessments interest and penalties	34,000
Amount of sales taxes expenses increase	281,000
Amount of net earnings decrease	$ 281,000